Fig. 3From: Efficacy and safety of IL-17 inhibitors for the treatment of ankylosing spondylitis: a systematic review and meta-analysisForest plot of the safety profile of IL-17 inhibitors in the treatment of patients with ankylosing spondylitis in terms of treatment-emergent adverse events (a), death (b), discontinuation due to adverse event (c), non-severe infections (d), or serious adverse events (e). RR, risk ratioBack to article page